Tikkanen-Dolenc, Heidi
,
Wadén, Johan
Forsblom, Carol
Harjutsalo, Valma
Thorn, Lena M.
Saraheimo, Markku
Elonen, Nina
Hietala, Kustaa
Summanen, Paula
Tikkanen, Heikki O.
Groop, Per-Henrik http://orcid.org/0000-0003-4055-6954
Funding for this research was provided by:
Please find attached (Please see Duality of Interest section, Disclosure of potential)
Article History
Received: 7 October 2019
Accepted: 5 November 2019
First Online: 20 November 2019
Compliance with ethical standards
:
: P-H.G. has received investigator-initiated research grants from Eli Lilly and Roche; is an advisory board member for Abbvie, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Novartis, Novo Nordisk and Sanofi; and has received lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Novartis, Novo Nordisk and Sanofi. No other potential conflicts of interest relevant to this article were reported.
: The study protocol was approved by the Ethical Committee of the Helsinki and Uusimaa Hospital District as well as by the local ethics committees at the participating centres and conducted according to the Declaration of Helsinki.
: The study protocol was approved by the Ethical Committee of the Helsinki and Uusimaa Hospital District as well as by the local ethics committees at the participating centres and conducted according to the Declaration of Helsinki.
: Before participation, all patients gave their written informed consent.